Skip to main content
Premium Trial:

Request an Annual Quote

Sense Biodetection: John Bishop

Sense Biodetection appointed John Bishop as a non-executive director.

Bishop, Cepheid's CEO from 2002 until its acquisition by Danaher in 2016, will play a pivotal strategic role at Sense as the company rapidly scales up production and distribution of its first products, including its COVID-19 test, Veros SARS-CoV-2.

At Cepheid, Bishop was instrumental in accelerating the firm's growth as a molecular diagnostics company. He oversaw the successful launch and commercialization of its GeneXpert and GeneXpert Xpress systems.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.